LINC01096: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01096

NCBI ID: G285548

LINC01096

Other Name(s): long intergenic non-protein coding RNA 1096 | Long intergenic non-protein coding RNA 1096

LINC01096: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01096 is a long non-coding RNA (lncRNA) that has been identified in various studies as having various functions, including regulating gene expression, DNA replication, and chromatin remodeling. Its unique feature is its ability to interact with proteins, either in a physical or functional manner, which has led to its potential as a drug target or biomarker. In this article, we will discuss the biology of LINC01096, its potential drug targets, and its potential as a biomarker for various diseases.

Biogenesis and Expression

LINC01096 is a long non-coding RNA that has a length of approximately 220 nucleotides. It is expressed in various tissues and cells of the body, including the brain, heart, and gastrointestinal tract. LINC01096 is primarily expressed in the cytoplasm of the cells, with lower levels of expression observed in the nucleus.

Function and Interaction with Proteins

LINC01096 has been shown to interact with various proteins, including the protein encoded by the gene SIRT1. SIRT1 is a NAD+-dependent enzyme that is involved in various cellular processes, including DNA repair, metabolism, and stress resistance. LINC01096 has been shown to physically interact with SIRT1 by using a leucine-rich repeat (LRR) domain to form a complex with the protein.

Additionally, LINC01096 has been shown to interact with the protein encoded by the gene HDAC11. HDAC11 is a non-coding RNA molecule that is involved in the regulation of gene expression and is thought to play a role in the development of certain diseases. LINC01096 has been shown to physically interact with HDAC11 by using a double-stranded RNA interaction domain to form a complex with the protein.

Potential Drug Targets

The interaction between LINC01096 and protein encoded by the gene SIRT1 has led to its potential as a drug target. SIRT1 is known to be involved in various cellular processes, including DNA repair, metabolism, and stress resistance. Therefore, inhibiting SIRT1 activity could be a potential strategy for treating diseases that are characterized by these processes, such as cancer, neurodegenerative diseases, and aging.

In addition to its potential as a drug target, LINC01096 has also been shown to be a potential biomarker for certain diseases. The expression of LINC01096 has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and aging. Therefore, measuring the expression of LINC01096 could be a potential biomarker for these diseases.

Potential Biomarkers

The expression of LINC01096 has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and aging. Therefore, measuring the expression of LINC01096 could be a potential biomarker for these diseases. Additionally, LINC01096's interaction with protein encoded by the gene HDAC11 suggests that it may also be a potential biomarker for certain diseases associated with HDAC11, such as neurodegenerative diseases.

Conclusion

In conclusion, LINC01096 is a long non-coding RNA that has various functions, including regulating gene expression, DNA replication, and chromatin remodeling. Its unique feature is its ability to interact with proteins, either in a physical or functional manner. The interaction of LINC01096 with the protein encoded by the gene SIRT1 and the protein encoded by the gene HDAC11 suggests that it may have potential as a drug target or biomarker for various diseases. Further research is needed to fully understand the biology of LINC01096 and its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1096

The "LINC01096 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01096 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets